Our pipeline

Portfolio Overview

Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs.

Femasys has an expansive, internally-created intellectual property portfolio with over 150 patents globally for our product candidates and our products.

Contraception Product Candidate

Research
Preclinical
PMA Clinical Studies
STAGE I
STAGE II
STAGE III

Contraception Product Candidate

Permanent Birth Control and Ultrasound Occlusion Confirmation

Research
Preclinical
PMA Clinical Studies
Anticipated Milestones
  • IDE approval achieved from FDA June 2023
  • Pivotal trial enrollment initiated August 2023

Infertility Products and Product Candidates

Research
Preclinical
Approval

INFERTILITY PRODUCTS

FemaSeed®

Intratubal Insemination

Research
Preclinical
Approval
Commercially Available
Anticipated Milestones
  • Commercialize in the U.S. in 2024
  • Enrollment completion of pivotal trial for male factor infertility expected Q4 2023

FemVue®

Contrast-Generating Device

Commercially Available
Anticipated Milestones
  • Expand commercialization

FemCath®

Selective Delivery Catheter

Commercially Available
Anticipated Milestones
  • Expand commercialization

Biopsy Product

Research
Preclinical
Approval

Biopsy Product

Endocervical Tissue Sampler

Research
Preclinical
Approval
Commercially Available
Anticipated Milestones
  • Expand commercialization

FemEMB™

Endometrial Biopsy

Family of three embracing

Permanent Birth Control

FemBloc®

FemBloc is in late-stage clinical development as the first and only in-office approach to permanent birth control without the need for anesthesia or special equipment, which would make this nonsurgical option easy to incorporate into existing practices worldwide. With a potential to be substantially less cost than the long-standing surgical alternative, FemBloc enriches the physician’s practice. FemBloc also features an innovative ultrasound approach to confirm success 90 days after the procedure.

Infertility

FemaSeed®

FemaSeed is an FDA-cleared, innovative infertility treatment that can be performed as a first-line therapeutic option. It is designed to deliver sperm to the fallopian tube where conception occurs to enhance natural fertilization. FemaSeed is less invasive and more affordable than assisted reproduction procedures, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Femvue® | FemCath®

FemVue is the first FDA-cleared product that delivers natural saline and air as contrast for diagnosis of the fallopian tubes with ultrasound. When paired with FemCath, an FDA-cleared intrauterine catheter, each tube can be selected for individual evaluation. This safe and reliable procedure provides real-time results and can be done along with a uterine cavity assessment for a comprehensive infertility diagnosis.

Other Products

FemCerv®

FemCerv is the first FDA-cleared product that obtains a comprehensive tissue sample in a virtually pain free procedure for the diagnosis of cervical cancer. We are marketing this diagnostic option alongside our other female-specific medical products to physicians’ offices.

Husband comforting wife as they meet with doctor about infertility